Literature DB >> 2072039

Oxidation-labile subfraction of human plasma low density lipoprotein isolated by ion-exchange chromatography.

H Shimano1, N Yamada, S Ishibashi, H Mokuno, N Mori, T Gotoda, K Harada, Y Akanuma, T Murase, Y Yazaki.   

Abstract

We isolated subfractions of human plasma low density lipoprotein (LDL) using ion-exchange chromatography. Plasma LDL from normolipidemic subjects were applied to a DEAE Sepharose 6B column. After elution of the bulk of LDL at 150 mM NaCl (the major fraction), the residual LDL was eluted at 500 mM NaCl and designated as the minor fraction. The minor fraction, only less than 1% of total LDL, tended to be somewhat similar in certain properties to oxidized LDL, e.g., an increased negative charge, higher protein/cholesterol ratio, and a higher flotation density than native LDL. These results were consistent with data reported by Avogaro et al. (1988. Arteriosclerosis. 8: 79-87). However, assays of 125I-labeled LDL binding activity for LDL receptors equal to that of the major fraction. Incorporation of [14C]oleate into cholesteryl ester [acyl-CoA:cholesterol acyltransferase (ACAT) activity] in mouse peritoneal macrophages incubated with the minor fraction was only slightly greater than that with the major fraction. Incubation of the minor fraction with 0.5 microM Cu2+ caused a remarkable stimulation of ACAT activity, while stimulation by the major fraction required incubation with 5 microM Cu2+, suggesting that the minor fraction was relatively labile to oxidation. The minor but definite presence of a plasma LDL subfraction more negative and susceptible to oxidation implicates the possibility of its association with atherogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2072039

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Negatively charged low-density lipoprotein is associated with atherogenic risk in hypertensive patients.

Authors:  Jungo Urata; Satoshi Ikeda; Seiji Koga; Tomoo Nakata; Tomohiko Yasunaga; Koichiro Sonoda; Yuji Koide; Naoto Ashizawa; Shigeru Kohno; Koji Maemura
Journal:  Heart Vessels       Date:  2011-04-14       Impact factor: 2.037

2.  Low-density lipoproteins inhibit histamine and NaNO2 relaxations of the coronary vasculature and reduce contractile function in isolated rat hearts.

Authors:  G J Harrison; L R Jordan; M L Selley; R J Willis
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

3.  Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity.

Authors:  G Schett; Q Xu; A Amberger; R Van der Zee; H Recheis; J Willeit; G Wick
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

4.  The expression of apolipoprotein B epitopes is normal in LDL of diabetic and end-stage renal disease patients.

Authors:  S Braschi; M Geoffrion; A Nguyen; Y Gaudreau; R W Milne
Journal:  Diabetologia       Date:  2006-04-04       Impact factor: 10.122

5.  Studies on epitopes on low-density lipoprotein modified by 4-hydroxynonenal. Biochemical characterization and determination.

Authors:  Q Chen; H Esterbauer; G Jürgens
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

6.  Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.

Authors:  P Holvoet; G Perez; Z Zhao; E Brouwers; H Bernar; D Collen
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

7.  Electronegative LDL Promotes Inflammation and Triglyceride Accumulation in Macrophages.

Authors:  Núria Puig; Lara Montolio; Pol Camps-Renom; Laia Navarra; Francesc Jiménez-Altayó; Elena Jiménez-Xarrié; Jose Luis Sánchez-Quesada; Sonia Benitez
Journal:  Cells       Date:  2020-03-01       Impact factor: 6.600

Review 8.  Electronegative LDL: a circulating modified LDL with a role in inflammation.

Authors:  Montserrat Estruch; José Luis Sánchez-Quesada; Jordi Ordóñez Llanos; Sònia Benítez
Journal:  Mediators Inflamm       Date:  2013-08-22       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.